Title of Collaborative Activity: |
A5349/TBTC S31 - Rifapentine - Containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-Label, Controlled Phase 3 Clinical Trial |
Description of Collaborative Activity: |
The purpose of this research initiative is to provide scientific discovery to improve patient care and safety by reducing the duration of treatment for drug-susceptible pulmonary tuberculosis to 4 months by using newregimens, including high-dose rifapentine. |
Type of Collaborative Activity: |
Research Initiative
|
Year the Collaborative Activity Originated: |
2015 |
NIH Participating Institutes/Centers/Office of the Director: |
NIAID |
HHS Agency Collaborators on this Activity: |
CDC |
